medigraphic.com
SPANISH

Biotecnología Aplicada

ISSN 1027-2852 (Electronic)
ISSN 0864-4551 (Print)
  • Contents
  • View Archive
  • Information
    • General Information        
    • Directory
  • Publish
    • Instructions for authors        
  • medigraphic.com
    • Home
    • Journals index            
    • Register / Login
  • Mi perfil

2016, Number 4

<< Back

Biotecnol Apl 2016; 33 (4)

Methodology for preparing the negotiation of biotechnological products and their associated intangible assets

García-Delgado D, Ortiz-Torres M, del Castillo L, Acevedo B, Martínez D, Castellanos A
Full text How to cite this article

Language: English
References: 9
Page: 4521-4523
PDF size: 185.04 Kb.


Key words:

pre-commercial payments, upfront payments, milestones, royalties, intagible assets.

ABSTRACT

The High Tech Enterprises (HTE) are playing an increasingly significant role in the economy, generating a substantial amount of intangible assets which are a significant part of the whole enterprise portfolio. In Cuba, the Biotechnology sector group a number of HTEs with intangible assets of great value in the context of the globalize market. Therefore, it is necessary to draw theoretical and practical frameworks for the negotiation of biotechnological products and their related intangible assets, and, particularly, to develop methodological tools for their adequate negotiation process. For that purpose, a documentary analysis followed by an expert survey was conducted to identify how much attention and the relevance that intangible assets received during the negotiations in HTEs at the BioCubaFarma biopharmaceutical enterprise. There was evident the lack of a standardized evaluation tool and a negotiation methodology for intangible assets. In this work, a new methodology for the valuation and negotiation of the intangible assets is presented. It was prepared by theoretical review of the literature available and designed by including the calculation methods, parameters and indicators required for their negotiation, and their adequate values and ranges both at pre-marketing and marketing commercialization stages. This work granted the Annual Award of the National Academy of Sciences of Cuba for the year 2015.


REFERENCES

  1. Kolchinsky P. The enterpreneur’s guide to a Biotech startup. 4th Edition. 2004 [cited 2015 Oct 16]. Available from: www.evelxa.com.

  2. BioSerentia, B.A. Guía de Valoración Económica-Financiera de Proyectos Biotechnológicos. Galicia: C.E.E.I Galicia, S.A.; 2010.

  3. Razgaitis R. Valuation and Dealmaking of Technology-Based Intellectual Property: Principles, Methods and Tools. 2nd edition. New York: Wiley; 2009.

  4. Verdovoto G. Opciones Reales: Una propuesta para valorar proyectos de Investigación y Desarrollo en Centros Públicos de Investigación. Universidad Auntónoma de Barcelona; 2010.

  5. Fernández P. Valoración Marcas e Intangibles. Navarra: Universidad de Navarra; 2007.

  6. Spacic O. Valuation of early stage technologies. How to Reach a Starting “Price” for Negotiating a TT Agreement. Noordwijk: TTO Circle - First Plenary Meeting. European Space Agency TTO Circle Initiative; 2011.

  7. Stewart JJ. Biotechnology valuations for the 21st century. Santa Mónica: Milken Institute; 2002.

  8. Poile S, Elvidge S. Early stage and discovery deals: Strategy, structure and payment. London: Bridgehead Pharmalicensing Group Ltd.; 2003.

  9. Kim WC, Mauborgne R. Blue Ocean Strategy: How to create uncontested market space and make competition irrelevant. New York: Harvard Business Review Press; 2005.




2020     |     www.medigraphic.com

Mi perfil

C?MO CITAR (Vancouver)

Biotecnol Apl. 2016;33